期刊文献+

影响肝型肝豆状核变性患者预后因素的探讨

Prognostic factors of Wilson disease with liver type
下载PDF
导出
摘要 目的探讨可预测肝型肝豆状核变性(WD)患者预后的相关因素。方法收集了75例肝型WD患者的临床和实验室资料,根据他们的预后分为肝A组50例(治疗后好转)和肝B组25例(治疗后恶化放弃治疗或死亡)。比较两组临床及实验室指标的差异,采用多因素Logistic回归分析探讨相关指标与患者预后的关系。结果肝A组和肝B组之间凝血酶原时间、血清总胆红素、AST、尿酸、血清白蛋白、载脂蛋白A1(ApoA1)比较差异具有统计学意义(P均<0.05);多因素Logistic回归分析结果显示凝血酶原时间、血清总胆红素、白蛋白、ApoA1是与肝型WD患者预后相关的独立因素(P均<0.05)。结论凝血酶原时间、血清总胆红素、白蛋白、ApoA1可作为评价WD患者预后的指标。 Objective To investigate useful predictive factors relating with the prognosis of Wilson disease (WD). Methods Clinical and laboratory data were collected from 75 consecutive paediatric WD pa- tients with liver type. They were divided respectively into two groups : group A ( relieved after treatment) and group B ( progressive or death after treatment) according to their effect with therapy. The clinical and laboratory indicators between the two groups were compared, and multivariate logistic regression analysis was used to ex- plore the relationship between relevant indicators and prognosis. Results The levels of prothrombin time, ser- um total bilirubin, transaminase, m,ie acid, albumin and Apolipoprotein A1 ( ApoA1 ) had significant differ- ences between two groups ( P 〈 0. 05 ). The level of prothrombin time, serum total bilirubin, Albumin and ApoA1 were independent factors to prognosis by Logistic regression analysis ( P 〈 0. 05). Conclusions Inde- pendent indicators of poor prognosis in patients with liver hepatic degeneration included albumin, ApoAl, pro- thrombin time and serum total bilirubin.
出处 《新医学》 2013年第10期685-688,共4页 Journal of New Medicine
基金 国家自然基金(81271327) 广东省科技计划项目(2011B031800015)
关键词 肝型 肝豆状核变性 预后因素 Liver type Wilson disease Prognosis factors
  • 相关文献

参考文献12

  • 1无.肝豆状核变性的诊断与治疗指南[J].中华神经科杂志,2008,41(8):566-569. 被引量:260
  • 2Altraif I, Handoo FA, Al Ghamdi H, et al. Presenta?tion, diagnosis and outcome of predominantly hepatic Wilson's disease in adult Saudi patients: a single centre experience. SaudiJ Gastroenterol, 2012, 18: 334-338.
  • 3Sternlieb 1. Wilson's disease. Clin Liver Di, 2000, 4: 229-239.
  • 4Fenu M, Liggi M, Demelia E, et al. Kayser-Fleischer ring in Wilson's disease: a cohort study. EurJ Intern Med, 2012, 23: e150-156.
  • 5Teodoro T, N eutel D, Lobo P, et al. Recovery after copper-deficiency myeloneuropathy in Wilson's disease.J Neurol, 2013, 260: 1917-1918.
  • 6Purchase R. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism. Sci Prog, 2013, 96: 19-32.
  • 7Tomi A, Dobrici V, Novakovi I, et al. Mutational anal?ysis of ATP7B gene and the genotype-phenotype correla?tion in patients with wilson's disease in serbia analiza mutacija ATP7B gena i genetsko-klinicka korelacija kod obolelih od Wilson-ove bolestiu Srbiji. Vojnosanit Pregl, 2013, 70: 457462.
  • 8Field LS, Luk E, Culotta vc. Copper chaperones: per?sonal escorts for metal ions.J Bioenerg Biomembr, 2002, 34: 373-379.
  • 9ArcayaJL, Tejeda CM, Salazar U, et al. Copper intox?ication decreases lifespan and induces neurologic altera?tions in drosophila melanogaster. Invest Clin, 2013, 54: 47-57.
  • 10Raitakari OT, M kinen VP, McQueen MJ, et al, Com?putationally estimated apolipoproteins B and Al in pre?dicting cardiovascular risk. Atherosclerosis, 2013, 226: 245-251.

二级参考文献12

  • 1梁秀龄,陈曦,李洵桦,黄丽,石铸,汤其强.肝豆状核变性临床若干问题[J].中华神经科杂志,2005,38(1):57-59. 被引量:54
  • 2Ala A, Walker AP, Ashkan K, et al. Wilson's disease. Lancet, 2007, 369:397-405.
  • 3Figus A, Angius A, Loudianos G, et al. Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations. Am J Hum Genet, 1995, 57: 1318-1324.
  • 4Roberts EA, Schilsky ML; Division Gastroenterology and Nutrition. A practice guideline on Wilson disease. Hepatology, 2003, 37 : 1475-1492.
  • 5Wilson DC ,Phillips M J, Cox DW, et al. Severe hepatic Wilson's disease in preschool-aged children. J Pediatr, 2000, 137: 719- 722.
  • 6Ala A, Borjigin J, Rochwarger A, et al. Wilson disease in septuagenarian siblings : Raising the bar for diagnosis. Hepatology, 2005, 41:668-670.
  • 7Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int, 2003,23 : 139-142.
  • 8Sinha S ,Taly AB. Withdrawal of peniciUamine from zinc sulphatepenicillamine maintance therapy in Wilson's disease : promising, safe and cheap. J Neurol Sci, 2008,264: 129-132.
  • 9Brewer GJ, Hedera P, Khin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: Ⅲ. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol, 2003,60: 379-385.
  • 10Brewer GJ. Novel therapeutic approaches to the treatment of Wilson's disease. Expert Opin Pharmacother, 2006, 7: 317-324.

共引文献259

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部